Clinical trial COBRIM
GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma
| Cancers | |
|---|---|
| Organ | Skin |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2012-00300-811 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01689519 |
| Inclusion criteria | BRAF V600 mutation |
| Last update |